
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2661542/publications.pdf Version: 2024-02-01



IÃI/ PCEN BAIOPATH

#	Article	IF	CITATIONS
1	Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery, 2004, 3, 935-949.	21.5	2,697
2	Polypharmacology: Challenges and Opportunities in Drug Discovery. Journal of Medicinal Chemistry, 2014, 57, 7874-7887.	2.9	813
3	Integration of virtual and high-throughput screening. Nature Reviews Drug Discovery, 2002, 1, 882-894.	21.5	782
4	Molecular Similarity in Medicinal Chemistry. Journal of Medicinal Chemistry, 2014, 57, 3186-3204.	2.9	448
5	QSAR without borders. Chemical Society Reviews, 2020, 49, 3525-3564.	18.7	427
6	Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discovery Today, 2007, 12, 225-233.	3.2	409
7	Current Trends in Ligand-Based Virtual Screening: Molecular Representations, Data Mining Methods, New Application Areas, and Performance Evaluation. Journal of Chemical Information and Modeling, 2010, 50, 205-216.	2.5	306
8	Exploring Activity Cliffs in Medicinal Chemistry. Journal of Medicinal Chemistry, 2012, 55, 2932-2942.	2.9	282
9	Application of Generative Autoencoder in <i>De Novo</i> Molecular Design. Molecular Informatics, 2018, 37, 1700123.	1.4	276
10	Interpretation of machine learning models using shapley values: application to compound potency and multi-target activity predictions. Journal of Computer-Aided Molecular Design, 2020, 34, 1013-1026.	1.3	248
11	Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications. Journal of Medicinal Chemistry, 2010, 53, 8461-8467.	2.9	223
12	Selected Concepts and Investigations in Compound Classification, Molecular Descriptor Analysis, and Virtual Screening. Journal of Chemical Information and Computer Sciences, 2001, 41, 233-245.	2.8	217
13	Recent Advances in Scaffold Hopping. Journal of Medicinal Chemistry, 2017, 60, 1238-1246.	2.9	213
14	State-of-the-art in ligand-based virtual screening. Drug Discovery Today, 2011, 16, 372-376.	3.2	196
15	MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs. Journal of Chemical Information and Modeling, 2012, 52, 1138-1145.	2.5	181
16	Interpretation of Compound Activity Predictions from Complex Machine Learning Models Using Local Approximations and Shapley Values. Journal of Medicinal Chemistry, 2020, 63, 8761-8777.	2.9	178
17	Recent Progress in Understanding Activity Cliffs and Their Utility in Medicinal Chemistry. Journal of Medicinal Chemistry, 2014, 57, 18-28.	2.9	174
18	SAR Index:  Quantifying the Nature of Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2007, 50, 5571-5578.	2.9	172

#	Article	IF	CITATIONS
19	Activity Landscape Representations for Structureâ^'Activity Relationship Analysis. Journal of Medicinal Chemistry, 2010, 53, 8209-8223.	2.9	163
20	Navigating structure–activity landscapes. Drug Discovery Today, 2009, 14, 698-705.	3.2	161
21	Structureâ^'Activity Relationship Anatomy by Network-like Similarity Graphs and Local Structureâ^'Activity Relationship Indices. Journal of Medicinal Chemistry, 2008, 51, 6075-6084.	2.9	143
22	New Methodologies for Ligand-Based Virtual Screening. Current Pharmaceutical Design, 2005, 11, 1189-1202.	0.9	139
23	Combinatorial Preferences Affect Molecular Similarity/Diversity Calculations Using Binary Fingerprints and Tanimoto Coefficients. Journal of Chemical Information and Computer Sciences, 2000, 40, 163-166.	2.8	138
24	Compound promiscuity: what can we learn from current data?. Drug Discovery Today, 2013, 18, 644-650.	3.2	135
25	Similarity searching. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2011, 1, 260-282.	6.2	117
26	Virtual Screening Methods that Complement HTS. Combinatorial Chemistry and High Throughput Screening, 2004, 7, 259-269.	0.6	113
27	Support vector machines for drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 93-104.	2.5	113
28	Charting Biologically Relevant Spirocyclic Compound Space. Chemistry - A European Journal, 2017, 23, 703-710.	1.7	107
29	Computational Exploration of Molecular Scaffolds in Medicinal Chemistry. Journal of Medicinal Chemistry, 2016, 59, 4062-4076.	2.9	100
30	How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. Journal of Medicinal Chemistry, 2017, 60, 3879-3886.	2.9	97
31	Development of Potent and Selective Inhibitors of <i>ecto</i> -5′-Nucleotidase Based on an Anthraquinone Scaffold. Journal of Medicinal Chemistry, 2010, 53, 2076-2086.	2.9	88
32	Scaffold Hopping Using Two-Dimensional Fingerprints: True Potential, Black Magic, or a Hopeless Endeavor? Guidelines for Virtual Screening. Journal of Medicinal Chemistry, 2010, 53, 5707-5715.	2.9	84
33	Lessons Learned from Molecular Scaffold Analysis. Journal of Chemical Information and Modeling, 2011, 51, 1742-1753.	2.5	82
34	Rationalizing Three-Dimensional Activity Landscapes and the Influence of Molecular Representations on Landscape Topology and the Formation of Activity Cliffs. Journal of Chemical Information and Modeling, 2010, 50, 1021-1033.	2.5	80
35	Computational analysis of ligand relationships within target families. Current Opinion in Chemical Biology, 2008, 12, 352-358.	2.8	79
36	Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme. Journal of Chemical Information and Computer Sciences, 2003, 43, 1151-1157.	2.8	78

#	Article	IF	CITATIONS
37	SARANEA: A Freely Available Program To Mine Structureâ^'Activity and Structureâ^'Selectivity Relationship Information in Compound Data Sets. Journal of Chemical Information and Modeling, 2010, 50, 68-78.	2.5	77
38	Local Structural Changes, Global Data Views: Graphical Substructureâ^'Activity Relationship Trailing. Journal of Medicinal Chemistry, 2011, 54, 2944-2951.	2.9	77
39	Large-Scale Similarity Search Profiling of ChEMBL Compound Data Sets. Journal of Chemical Information and Modeling, 2011, 51, 1831-1839.	2.5	76
40	Evolving Concept of Activity Cliffs. ACS Omega, 2019, 4, 14360-14368.	1.6	76
41	Support Vector Machine Classification and Regression Prioritize Different Structural Features for Binary Compound Activity and Potency Value Prediction. ACS Omega, 2017, 2, 6371-6379.	1.6	75
42	The Future of Virtual Compound Screening. Chemical Biology and Drug Design, 2013, 81, 33-40.	1.5	74
43	Profile Scaling Increases the Similarity Search Performance of Molecular Fingerprints Containing Numerical Descriptors and Structural Keys. Journal of Chemical Information and Computer Sciences, 2003, 43, 1218-1225.	2.8	69
44	Identification of the First Low-Molecular-Weight Inhibitors of Matriptase-2. Journal of Medicinal Chemistry, 2010, 53, 5523-5535.	2.9	67
45	Database Searching for Compounds with Similar Biological Activity Using Short Binary Bit String Representations of Molecules. Journal of Chemical Information and Computer Sciences, 1999, 39, 881-886.	2.8	65
46	Advancing the activity cliff concept. F1000Research, 2013, 2, 199.	0.8	65
47	Synthesis, biological evaluation and molecular docking of N-phenyl thiosemicarbazones as urease inhibitors. Bioorganic Chemistry, 2015, 61, 51-57.	2.0	65
48	Data structures and computational tools for the extraction of SAR information from large compound sets. Drug Discovery Today, 2010, 15, 630-639.	3.2	64
49	Ligand Prediction for Orphan Targets Using Support Vector Machines and Various Target-Ligand Kernels Is Dominated by Nearest Neighbor Effects. Journal of Chemical Information and Modeling, 2009, 49, 2155-2167.	2.5	63
50	Integrating Structure―and Ligandâ€Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets. ChemMedChem, 2008, 3, 1566-1571.	1.6	62
51	Support-Vector-Machine-Based Ranking Significantly Improves the Effectiveness of Similarity Searching Using 2D Fingerprints and Multiple Reference Compounds. Journal of Chemical Information and Modeling, 2008, 48, 742-746.	2.5	61
52	BindingDB and ChEMBL: online compound databases for drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 683-687.	2.5	60
53	Fingerprint Scaling Increases the Probability of Identifying Molecules with Similar Activity in Virtual Screening Calculations. Journal of Chemical Information and Computer Sciences, 2001, 41, 746-753.	2.8	59
54	Molecular Similarity Analysis Uncovers Heterogeneous Structure-Activity Relationships and Variable Activity Landscapes. Chemistry and Biology, 2007, 14, 489-497.	6.2	59

#	Article	IF	CITATIONS
55	Chemical space networks: a powerful new paradigm for the description of chemical space. Journal of Computer-Aided Molecular Design, 2014, 28, 795-802.	1.3	59
56	Chemical Substitutions That Introduce Activity Cliffs Across Different Compound Classes and Biological Targets. Journal of Chemical Information and Modeling, 2010, 50, 1248-1256.	2.5	57
57	Searching for Target-Selective Compounds Using Different Combinations of Multiclass Support Vector Machine Ranking Methods, Kernel Functions, and Fingerprint Descriptors. Journal of Chemical Information and Modeling, 2009, 49, 582-592.	2.5	56
58	Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs. Journal of Chemical Information and Modeling, 2010, 50, 2112-2118.	2.5	56
59	Similarityâ^'Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules. Journal of Chemical Information and Modeling, 2010, 50, 1395-1409.	2.5	56
60	Current Compound Coverage of the Kinome. Journal of Medicinal Chemistry, 2015, 58, 30-40.	2.9	56
61	Systematic Extraction of Analogue Series from Large Compound Collections Using a New Computational Compound–Core Relationship Method. ACS Omega, 2019, 4, 1027-1032.	1.6	56
62	Differential Shannon Entropy as a Sensitive Measure of Differences in Database Variability of Molecular Descriptors. Journal of Chemical Information and Computer Sciences, 2001, 41, 1060-1066.	2.8	54
63	Extending the Activity Cliff Concept: Structural Categorization of Activity Cliffs and Systematic Identification of Different Types of Cliffs in the ChEMBL Database. Journal of Chemical Information and Modeling, 2012, 52, 1806-1811.	2.5	54
64	Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: Synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis. Bioorganic and Medicinal Chemistry, 2014, 22, 6163-6173.	1.4	54
65	EXPLORING COMPOUND PROMISCUITY PATTERNS AND MULTI-TARGET ACTIVITY SPACES. Computational and Structural Biotechnology Journal, 2014, 9, e201401003.	1.9	54
66	Entering the â€~big data' era in medicinal chemistry: molecular promiscuity analysis revisited. Future Science OA, 2017, 3, FSO179.	0.9	53
67	Memory-assisted reinforcement learning for diverse molecular de novo design. Journal of Cheminformatics, 2020, 12, 68.	2.8	53
68	Evaluation of Descriptors and Mini-Fingerprints for the Identification of Molecules with Similar Activity. Journal of Chemical Information and Computer Sciences, 2000, 40, 1227-1234.	2.8	52
69	From Structure–Activity to Structure–Selectivity Relationships: Quantitative Assessment, Selectivity Cliffs, and Key Compounds. ChemMedChem, 2009, 4, 1864-1873.	1.6	51
70	Ligand Prediction from Protein Sequence and Small Molecule Information Using Support Vector Machines and Fingerprint Descriptors. Journal of Chemical Information and Modeling, 2009, 49, 767-779.	2.5	50
71	Prediction of Activity Cliffs Using Support Vector Machines. Journal of Chemical Information and Modeling, 2012, 52, 2354-2365.	2.5	50
72	Matched molecular pairs derived by retrosynthetic fragmentation. MedChemComm, 2014, 5, 64-67.	3.5	50

#	Article	IF	CITATIONS
73	Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. Journal of Medicinal Chemistry, 2016, 59, 7667-7676.	2.9	50
74	SAR Matrices: Automated Extraction of Information-Rich SAR Tables from Large Compound Data Sets. Journal of Chemical Information and Modeling, 2012, 52, 1769-1776.	2.5	49
75	Computer-aided drug discovery. F1000Research, 2015, 4, 630.	0.8	49
76	Multitask Machine Learning for Classifying Highly and Weakly Potent Kinase Inhibitors. ACS Omega, 2019, 4, 4367-4375.	1.6	49
77	Design of Multitarget Activity Landscapes That Capture Hierarchical Activity Cliff Distributions. Journal of Chemical Information and Modeling, 2011, 51, 258-266.	2.5	48
78	From Activity Cliffs to Activity Ridges: Informative Data Structures for SAR Analysis. Journal of Chemical Information and Modeling, 2011, 51, 1848-1856.	2.5	47
79	Virtual Screening Identifies Novel Sulfonamide Inhibitors of <i>ecto</i> -5′-Nucleotidase. Journal of Medicinal Chemistry, 2012, 55, 6576-6581.	2.9	47
80	Characterization of P2X4 receptor agonists and antagonists by calcium influx and radioligand binding studies. Biochemical Pharmacology, 2017, 125, 41-54.	2.0	47
81	Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?. Journal of Medicinal Chemistry, 2019, 62, 10497-10525.	2.9	47
82	Cathepsin B: Active site mapping with peptidic substrates and inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 1-15.	1.4	47
83	Comparison of 2D Fingerprint Methods for Multiple-Template Similarity Searching on Compound Activity Classes of Increasing Structural Diversity. ChemMedChem, 2007, 2, 208-217.	1.6	46
84	Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors. Bioorganic Chemistry, 2016, 68, 177-186.	2.0	46
85	Molecular Scaffolds with High Propensity to Form Multi-Target Activity Cliffs. Journal of Chemical Information and Modeling, 2010, 50, 500-510.	2.5	45
86	Methods for SAR visualization. RSC Advances, 2012, 2, 369-378.	1.7	45
87	Learning from â€~big data': compounds and targets. Drug Discovery Today, 2014, 19, 357-360.	3.2	45
88	A Coumarin‣abeled Vinyl Sulfone as Tripeptidomimetic Activityâ€Based Probe for Cysteine Cathepsins. ChemBioChem, 2014, 15, 955-959.	1.3	45
89	Emerging Chemical Patterns:  A New Methodology for Molecular Classification and Compound Selection. Journal of Chemical Information and Modeling, 2006, 46, 2502-2514.	2.5	44
90	Systematic computational analysis of structure–activity relationships: concepts, challenges and recent advances. Future Medicinal Chemistry, 2009, 1, 451-466.	1.1	44

#	Article	IF	CITATIONS
91	Chemoinformatics: A view of the field and current trends in method development. Bioorganic and Medicinal Chemistry, 2012, 20, 5317-5323.	1.4	44
92	Virtual compound screening in drug discovery. Future Medicinal Chemistry, 2012, 4, 593-602.	1.1	44
93	Evolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery. Journal of Computer-Aided Molecular Design, 2022, 36, 355-362.	1.3	44
94	Systematic Analysis of Public Domain Compound Potency Data Identifies Selective Molecular Scaffolds across Druggable Target Families. Journal of Medicinal Chemistry, 2010, 53, 752-758.	2.9	43
95	Large-scale exploration of bioisosteric replacements on the basis of matched molecular pairs. Future Medicinal Chemistry, 2011, 3, 425-436.	1.1	43
96	Modeling of activity landscapes for drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 463-473.	2.5	43
97	Determining the Degree of Promiscuity of Extensively Assayed Compounds. PLoS ONE, 2016, 11, e0153873.	1.1	43
98	Analysis of structure-based virtual screening studies and characterization of identified active compounds. Future Medicinal Chemistry, 2012, 4, 603-613.	1.1	42
99	Informatics for Chemistry, Biology, and Biomedical Sciences. Journal of Chemical Information and Modeling, 2021, 61, 26-35.	2.5	42
100	Molecular Similarity Analysis and Virtual Screening by Mapping of Consensus Positions in Binary-Transformed Chemical Descriptor Spaces with Variable Dimensionality. Journal of Chemical Information and Computer Sciences, 2004, 44, 21-29.	2.8	41
101	Matched Molecular Pair Analysis of Small Molecule Microarray Data Identifies Promiscuity Cliffs and Reveals Molecular Origins of Extreme Compound Promiscuity. Journal of Medicinal Chemistry, 2012, 55, 10220-10228.	2.9	41
102	Activity-relevant similarity values for fingerprints and implications for similarity searching. F1000Research, 2016, 5, 591.	0.8	41
103	Improving the Search Performance of Extended Connectivity Fingerprints through Activityâ€Oriented Feature Filtering and Application of a Bitâ€Densityâ€Dependent Similarity Function. ChemMedChem, 2009, 4, 540-548.	1.6	40
104	Composition and Topology of Activity Cliff Clusters Formed by Bioactive Compounds. Journal of Chemical Information and Modeling, 2014, 54, 451-461.	2.5	40
105	Representation and identification of activity cliffs. Expert Opinion on Drug Discovery, 2017, 12, 879-883.	2.5	40
106	Artificial Intelligence in Drug Discovery: Into the Great Wide Open. Journal of Medicinal Chemistry, 2020, 63, 8651-8652.	2.9	40
107	Comparison of Confirmed Inactive and Randomly Selected Compounds as Negative Training Examples in Support Vector Machine-Based Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 1595-1601.	2.5	39
108	High-resolution view of compound promiscuity. F1000Research, 2013, 2, 144.	0.8	39

#	Article	IF	CITATIONS
109	Design and Evaluation of a Novel Class-Directed 2D Fingerprint to Search for Structurally Diverse Active Compounds. Journal of Chemical Information and Modeling, 2006, 46, 2515-2526.	2.5	38
110	Design of chemical space networks using a Tanimoto similarity variant based upon maximum common substructures. Journal of Computer-Aided Molecular Design, 2015, 29, 937-950.	1.3	38
111	Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. Journal of Medicinal Chemistry, 2016, 59, 10285-10290.	2.9	38
112	Three-Dimensional Similarity in Molecular Docking: Prioritizing Ligand Poses on the Basis of Experimental Binding Modes. Journal of Chemical Information and Modeling, 2016, 56, 580-587.	2.5	38
113	Methods for Computerâ€aided Chemical Biology. Part 2: Evaluation of Compound Selectivity Using 2D Molecular Fingerprints. Chemical Biology and Drug Design, 2007, 70, 195-205.	1.5	37
114	Similarity Searching Using Fingerprints of Molecular Fragments Involved in Proteinâ^'Ligand Interactions. Journal of Chemical Information and Modeling, 2008, 48, 2308-2312.	2.5	37
115	Molecular Fingerprint Recombination: Generating Hybrid Fingerprints for Similarity Searching from Different Fingerprint Types. ChemMedChem, 2009, 4, 1859-1863.	1.6	37
116	Growth of Ligand–Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity. Journal of Chemical Information and Modeling, 2012, 52, 2550-2558.	2.5	37
117	Visualization and Interpretation of Support Vector Machine Activity Predictions. Journal of Chemical Information and Modeling, 2015, 55, 1136-1147.	2.5	37
118	Activity-relevant similarity values for fingerprints and implications for similarity searching. F1000Research, 2016, 5, 591.	0.8	37
119	Accurate Partitioning of Compounds Belonging to Diverse Activity Classes. Journal of Chemical Information and Computer Sciences, 2002, 42, 757-764.	2.8	36
120	Recursive Median Partitioning for Virtual Screening of Large Databases. Journal of Chemical Information and Computer Sciences, 2003, 43, 182-188.	2.8	36
121	Structural Interpretation of Activity Cliffs Revealed by Systematic Analysis of Structureâ^Activity Relationships in Analog Series. Journal of Chemical Information and Modeling, 2009, 49, 2179-2189.	2.5	36
122	What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data. AAPS Journal, 2013, 15, 808-815.	2.2	36
123	Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations. Journal of Chemical Information and Modeling, 2006, 46, 1937-1944.	2.5	34
124	Methods for Computerâ€Aided Chemical Biology. Part 3: Analysis of Structure–Selectivity Relationships through Single―or Dualâ€Step Selectivity Searching and Bayesian Classification. Chemical Biology and Drug Design, 2008, 71, 518-528.	1.5	34
125	Targeting Multifunctional Proteins by Virtual Screening: Structurally Diverse Cytohesin Inhibitors with Differentiated Biological Functions. ACS Chemical Biology, 2010, 5, 839-849.	1.6	34
126	Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors. European Journal of Medicinal Chemistry, 2014, 78, 106-117.	2.6	34

#	Article	IF	CITATIONS
127	Machine Learning Models for Accurate Prediction of Kinase Inhibitors with Different Binding Modes. Journal of Medicinal Chemistry, 2020, 63, 8738-8748.	2.9	34
128	Current Trends, Overlooked Issues, and Unmet Challenges in Virtual Screening. Journal of Chemical Information and Modeling, 2020, 60, 4112-4115.	2.5	34
129	High-resolution view of compound promiscuity. F1000Research, 2013, 2, 144.	0.8	34
130	Explainable Machine Learning for Property Predictions in Compound Optimization. Journal of Medicinal Chemistry, 2021, 64, 17744-17752.	2.9	34
131	Median Partitioning:  A Novel Method for the Selection of Representative Subsets from Large Compound Pools. Journal of Chemical Information and Computer Sciences, 2002, 42, 885-893.	2.8	33
132	Anatomy of Fingerprint Search Calculations on Structurally Diverse Sets of Active Compounds. Journal of Chemical Information and Modeling, 2005, 45, 1812-1819.	2.5	33
133	Ligand-Target Interaction-Based Weighting of Substructures for Virtual Screening. Journal of Chemical Information and Modeling, 2008, 48, 1955-1964.	2.5	33
134	Identification of sulfonic acids as efficient ecto-5′-nucleotidase inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 685-691.	2.6	33
135	Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds. Journal of Medicinal Chemistry, 2022, 65, 922-934.	2.9	33
136	Identification of Structurally Diverse Growth Hormone Secretagogue Agonists by Virtual Screening and Structureâ^Activity Relationship Analysis of 2-Formylaminoacetamide Derivatives. Journal of Medicinal Chemistry, 2004, 47, 4286-4290.	2.9	32
137	How Promiscuous Are Pharmaceutically Relevant Compounds? A Data-Driven Assessment. AAPS Journal, 2013, 15, 104-111.	2.2	32
138	Influence of Search Parameters and Criteria on Compound Selection, Promiscuity, and Pan Assay Interference Characteristics. Journal of Chemical Information and Modeling, 2014, 54, 3056-3066.	2.5	32
139	Prediction of Compound Profiling Matrices Using Machine Learning. ACS Omega, 2018, 3, 4713-4723.	1.6	32
140	Balancing the Influence of Molecular Complexity on Fingerprint Similarity Searching. Journal of Chemical Information and Modeling, 2008, 48, 75-84.	2.5	31
141	Formal Concept Analysis for the Identification of Molecular Fragment Combinations Specific for Active and Highly Potent Compounds. Journal of Medicinal Chemistry, 2008, 51, 5342-5348.	2.9	31
142	Inhibition of Human Leukocyte Elastase by Brunsvicamides A–C: Cyanobacterial Cyclic Peptides. ChemMedChem, 2009, 4, 1425-1429.	1.6	31
143	Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. Journal of Chemical Information and Modeling, 2015, 55, 676-686.	2.5	31
144	Similarity Search Profiling Reveals Effects of Fingerprint Scaling in Virtual Screening. Journal of Chemical Information and Computer Sciences, 2004, 44, 2032-2039.	2.8	30

#	Article	IF	CITATIONS
145	Mapping Algorithms for Molecular Similarity Analysis and Ligand-Based Virtual Screening:Â Design of DynaMAD and Comparison with MAD and DMC. Journal of Chemical Information and Modeling, 2006, 46, 1623-1634.	2.5	30
146	Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations. Journal of Chemical Information and Modeling, 2007, 47, 59-68.	2.5	30
147	How Do 2D Fingerprints Detect Structurally Diverse Active Compounds? Revealing Compound Subset-Specific Fingerprint Features through Systematic Selection. Journal of Chemical Information and Modeling, 2011, 51, 2254-2265.	2.5	30
148	Comprehensive Analysis of Single―and Multiâ€Target Activity Cliffs Formed by Currently Available Bioactive Compounds. Chemical Biology and Drug Design, 2011, 78, 224-228.	1.5	30
149	Design and characterization of chemical space networks for different compound data sets. Journal of Computer-Aided Molecular Design, 2015, 29, 113-125.	1.3	30
150	Partitioning Methods for the Identification of Active Molecules. Current Medicinal Chemistry, 2003, 10, 707-715.	1.2	29
151	Methods for Computerâ€aided Chemical Biology. Part 1: Design of a Benchmark System for the Evaluation of Compound Selectivity. Chemical Biology and Drug Design, 2007, 70, 182-194.	1.5	29
152	Development of a Fingerprint Reduction Approach for Bayesian Similarity Searching Based on Kullbackâ	2.5	29
153	Exploration of Structureâ^'Activity Relationship Determinants in Analogue Series. Journal of Medicinal Chemistry, 2009, 52, 3212-3224.	2.9	28
154	A Homogeneous Fluorescence Resonance Energy Transfer System for Monitoring the Activation of a Protein Switch in Real Time. Journal of the American Chemical Society, 2011, 133, 8372-8379.	6.6	28
155	Prediction of Activity Cliffs Using Condensed Graphs of Reaction Representations, Descriptor Recombination, Support Vector Machine Classification, and Support Vector Regression. Journal of Chemical Information and Modeling, 2016, 56, 1631-1640.	2.5	28
156	Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry. Future Science OA, 2016, 2, FSO149.	0.9	28
157	Molecular Similarity Concepts for Informatics Applications. Methods in Molecular Biology, 2017, 1526, 231-245.	0.4	28
158	Design of an Activity-Based Probe for Human Neutrophil Elastase: Implementation of the Lossen Rearrangement To Induce Förster Resonance Energy Transfers. Biochemistry, 2018, 57, 742-752.	1.2	28
159	Combining structural and bioactivity-based fingerprints improves prediction performance and scaffoldÂhopping capability. Journal of Cheminformatics, 2019, 11, 54.	2.8	28
160	Evaluating the High-Throughput Screening Computations. Journal of Biomolecular Screening, 2005, 10, 649-652.	2.6	27
161	Bayesian Interpretation of a Distance Function for Navigating High-Dimensional Descriptor Spaces. Journal of Chemical Information and Modeling, 2007, 47, 39-46.	2.5	27
162	Bit Silencing in Fingerprints Enables the Derivation of Compound Class-Directed Similarity Metrics. Journal of Chemical Information and Modeling, 2008, 48, 1754-1759.	2.5	27

#	Article	IF	CITATIONS
163	Frequency of Occurrence and Potency Range Distribution of Activity Cliffs in Bioactive Compounds. Journal of Chemical Information and Modeling, 2012, 52, 2348-2353.	2.5	27
164	Monitoring the Progression of Structure–Activity Relationship Information during Lead Optimization. Journal of Medicinal Chemistry, 2016, 59, 4235-4244.	2.9	27
165	Influence of Varying Training Set Composition and Size on Support Vector Machine-Based Prediction of Active Compounds. Journal of Chemical Information and Modeling, 2017, 57, 710-716.	2.5	27
166	POT-DMC:Â A Virtual Screening Method for the Identification of Potent Hits. Journal of Medicinal Chemistry, 2004, 47, 5608-5611.	2.9	26
167	Introduction of an Information-Theoretic Method to Predict Recovery Rates of Active Compounds for Bayesian in Silico Screening:  Theory and Screening Trials. Journal of Chemical Information and Modeling, 2007, 47, 337-341.	2.5	26
168	Apparent Asymmetry in Fingerprint Similarity Searching is a Direct Consequence of Differences in Bit Densities and Molecular Size. ChemMedChem, 2007, 2, 1037-1042.	1.6	26
169	Bayesian Screening for Active Compounds in Highâ€dimensional Chemical Spaces Combining Property Descriptors and Molecular Fingerprints. Chemical Biology and Drug Design, 2008, 71, 8-14.	1.5	26
170	Combining Cluster Analysis, Feature Selection and Multiple Support Vector Machine Models for the Identification of Human Etherâ€aâ€goâ€go Related Gene Channel Blocking Compounds. Chemical Biology and Drug Design, 2009, 73, 17-25.	1.5	26
171	Computational Analysis of Multiâ€ŧarget Structure–Activity Relationships to Derive Preference Orders for Chemical Modifications toward Target Selectivity. ChemMedChem, 2010, 5, 847-858.	1.6	26
172	Systematic Identification and Classification of Three-Dimensional Activity Cliffs. Journal of Chemical Information and Modeling, 2012, 52, 1490-1498.	2.5	26
173	Advances in Activity Cliff Research. Molecular Informatics, 2016, 35, 181-191.	1.4	26
174	Systematic Artifacts in Support Vector Regression-Based Compound Potency Prediction Revealed by Statistical and Activity Landscape Analysis. PLoS ONE, 2015, 10, e0119301.	1.1	26
175	Mini-fingerprints for virtual screening: Design principles and generation of novel prototypes based on information theory. SAR and QSAR in Environmental Research, 2003, 14, 27-40.	1.0	25
176	A Distance Function for Retrieval of Active Molecules from Complex Chemical Space Representations. Journal of Chemical Information and Modeling, 2006, 46, 1094-1097.	2.5	25
177	Elucidation of Structureâ^'Activity Relationship Pathways in Biological Screening Data. Journal of Medicinal Chemistry, 2009, 52, 1075-1080.	2.9	25
178	Global assessment of scaffold hopping potential for current pharmaceutical targets. MedChemComm, 2010, 1, 339-344.	3.5	25
179	A Data Mining Method To Facilitate SAR Transfer. Journal of Chemical Information and Modeling, 2011, 51, 1857-1866.	2.5	25
180	Development of a Method To Consistently Quantify the Structural Distance between Scaffolds and To Assess Scaffold Hopping Potential. Journal of Chemical Information and Modeling, 2011, 51, 2507-2514.	2.5	25

#	Article	IF	CITATIONS
181	Lessons learned from the design of chemical space networks and opportunities for new applications. Journal of Computer-Aided Molecular Design, 2016, 30, 191-208.	1.3	25
182	Computational scaffold hopping: cornerstone for the future of drug design?. Future Medicinal Chemistry, 2017, 9, 629-631.	1.1	25
183	Isonicotinohydrazones as inhibitors of alkaline phosphatase and ectoâ€5′â€nucleotidase. Chemical Biology and Drug Design, 2017, 89, 365-370.	1.5	25
184	Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical Matter. Journal of Medicinal Chemistry, 2018, 61, 10255-10264.	2.9	25
185	Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome. ACS Omega, 2018, 3, 17295-17308.	1.6	25
186	Introduction of a Generally Applicable Method to Estimate Retrieval of Active Molecules for Similarity Searching using Fingerprints. ChemMedChem, 2007, 2, 1311-1320.	1.6	24
187	Computational Methodologies for Compound Database Searching that Utilize Experimental Protein–Ligand Interaction Information. Chemical Biology and Drug Design, 2010, 76, 191-200.	1.5	24
188	Systematic Assessment of Compound Series with SAR Transfer Potential. Journal of Chemical Information and Modeling, 2012, 52, 3138-3143.	2.5	24
189	Assessing the Target Differentiation Potential of Imidazole-Based Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 11067-11071.	2.9	24
190	Predicting Potent Compounds via Model-Based Global Optimization. Journal of Chemical Information and Modeling, 2013, 53, 553-559.	2.5	24
191	New Frontiers in Kinases: Second Generation Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 2167-2168.	2.9	24
192	Activity profiles of analog series containing pan assay interference compounds. RSC Advances, 2017, 7, 35638-35647.	1.7	24
193	Determination and Mapping of Activity-Specific Descriptor Value Ranges for the Identification of Active Compounds. Journal of Medicinal Chemistry, 2006, 49, 2284-2293.	2.9	23
194	Towards Unified Compound Screening Strategies: A Critical Evaluation of Error Sources in Experimental and Virtual High-Throughput Screening. QSAR and Combinatorial Science, 2006, 25, 1153-1161.	1.5	23
195	Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery. Expert Opinion on Drug Discovery, 2008, 3, 1371-1376.	2.5	23
196	Reduction and Recombination of Fingerprints of Different Design Increase Compound Recall and the Structural Diversity of Hits. Chemical Biology and Drug Design, 2010, 75, 152-160.	1.5	23
197	Exploration of 3D Activity Cliffs on the Basis of Compound Binding Modes and Comparison of 2D and 3D Cliffs. Journal of Chemical Information and Modeling, 2012, 52, 670-677.	2.5	23
198	Activity Landscapes, Information Theory, and Structure – Activity Relationships. Molecular Informatics, 2013, 32, 421-430.	1.4	23

#	Article	IF	CITATIONS
199	Do Medicinal Chemists Learn from Activity Cliffs? A Systematic Evaluation of Cliff Progression in Evolving Compound Data Sets. Journal of Medicinal Chemistry, 2013, 56, 3339-3345.	2.9	23
200	Prediction of Compounds with Closely Related Activity Profiles Using Weighted Support Vector Machine Linear Combinations. Journal of Chemical Information and Modeling, 2013, 53, 791-801.	2.5	23
201	Systematic Identification of Scaffolds Representing Compounds Active against Individual Targets and Single or Multiple Target Families. Journal of Chemical Information and Modeling, 2013, 53, 312-326.	2.5	23
202	Substrate specificity of human matriptase-2. Biochimie, 2014, 97, 121-127.	1.3	23
203	Rationality over fashion and hype in drug design. F1000Research, 2021, 10, 397.	0.8	23
204	Advancing the activity cliff concept, part II. F1000Research, 2014, 3, 75.	0.8	23
205	Scaffold Distributions in Bioactive Molecules, Clinical Trials Compounds, and Drugs. ChemMedChem, 2010, 5, 187-190.	1.6	22
206	X-ray Structures of Target–Ligand Complexes Containing Compounds with Assay Interference Potential. Journal of Medicinal Chemistry, 2018, 61, 1276-1284.	2.9	22
207	The †SAR Matrix' method and its extensions for applications in medicinal chemistry and chemogenomics. F1000Research, 2014, 3, 113.	0.8	22
208	REPROVIS-DB: A Benchmark System for Ligand-Based Virtual Screening Derived from Reproducible Prospective Applications. Journal of Chemical Information and Modeling, 2011, 51, 2467-2473.	2.5	21
209	Advances in Computational Medicinal Chemistry: Matched Molecular Pair Analysis. Drug Development Research, 2012, 73, 518-527.	1.4	21
210	Exploring the Scaffold Universe of Kinase Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 315-332.	2.9	21
211	Comprehensive Analysis of Three-Dimensional Activity Cliffs Formed by Kinase Inhibitors with Different Binding Modes and Cliff Mapping of Structural Analogues. Journal of Medicinal Chemistry, 2015, 58, 252-264.	2.9	21
212	Identification of Compounds That Interfere with Highâ€Throughput Screening Assay Technologies. ChemMedChem, 2019, 14, 1795-1802.	1.6	21
213	State-of-the-art of artificial intelligence in medicinal chemistry. Future Science OA, 2021, 7, FSO702.	0.9	21
214	Mining of Randomly Generated Molecular Fragment Populations Uncovers Activity-Specific Fragment Hierarchies. Journal of Chemical Information and Modeling, 2007, 47, 1405-1413.	2.5	20
215	Introduction of the Conditional Correlated Bernoulli Model of Similarity Value Distributions and its Application to the Prospective Prediction of Fingerprint Search Performance. Journal of Chemical Information and Modeling, 2011, 51, 2496-2506.	2.5	20
216	SAR Monitoring of Evolving Compound Data Sets Using Activity Landscapes. Journal of Chemical Information and Modeling, 2011, 51, 532-540.	2.5	20

#	Article	IF	CITATIONS
217	Classification of Compounds with Distinct or Overlapping Multi-Target Activities and Diverse Molecular Mechanisms Using Emerging Chemical Patterns. Journal of Chemical Information and Modeling, 2013, 53, 1272-1281.	2.5	20
218	Neighborhood-Based Prediction of Novel Active Compounds from SAR Matrices. Journal of Chemical Information and Modeling, 2014, 54, 801-809.	2.5	20
219	Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-13.	0.5	20
220	Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activityâ€Based Probes of Matriptaseâ€2. Chemistry - A European Journal, 2016, 22, 8525-8535.	1.7	20
221	Promiscuity of inhibitors of human protein kinases at varying data confidence levels and test frequencies. RSC Advances, 2017, 7, 41265-41271.	1.7	20
222	Prediction of Compound Profiling Matrices, Part II: Relative Performance of Multitask Deep Learning and Random Forest Classification on the Basis of Varying Amounts of Training Data. ACS Omega, 2018, 3, 12033-12040.	1.6	20
223	Virtual Screening with Generative Topographic Maps: How Many Maps Are Required?. Journal of Chemical Information and Modeling, 2019, 59, 564-572.	2.5	20
224	Distribution of Molecular Scaffolds and R-Groups Isolated from Large Compound Databases. Journal of Molecular Modeling, 1999, 5, 97-102.	0.8	19
225	Bayesian Similarity Searching in High-Dimensional Descriptor Spaces Combined with Kullback-Leibler Descriptor Divergence Analysis. Journal of Chemical Information and Modeling, 2008, 48, 247-255.	2.5	19
226	Extracting SAR Information from a Large Collection of Anti-Malarial Screening Hits by NSC-SPT Analysis. ACS Medicinal Chemistry Letters, 2011, 2, 201-206.	1.3	19
227	Comparison of bioactive chemical space networks generated using substructure- and fingerprint-based measures of molecular similarity. Journal of Computer-Aided Molecular Design, 2015, 29, 595-608.	1.3	19
228	En Route to New Therapeutic Options for Iron Overload Diseases: Matriptaseâ€2 as a Target for Kunitzâ€Type Inhibitors. ChemBioChem, 2016, 17, 595-604.	1.3	19
229	X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design. ACS Omega, 2018, 3, 106-111.	1.6	19
230	Integrating the Structure–Activity Relationship Matrix Method with Molecular Grid Maps and Activity Landscape Models for Medicinal Chemistry Applications. ACS Omega, 2019, 4, 7061-7069.	1.6	19
231	Molecular Similarity Concepts and Search Calculations. Methods in Molecular Biology, 2008, 453, 327-347.	0.4	18
232	Atom-Centered Interacting Fragments and Similarity Search Applications. Journal of Chemical Information and Modeling, 2010, 50, 79-86.	2.5	18
233	Chemical Transformations That Yield Compounds with Distinct Activity Profiles. ACS Medicinal Chemistry Letters, 2011, 2, 523-527.	1.3	18
234	A Perspective on Computational Chemogenomics. Molecular Informatics, 2013, 32, 1025-1028.	1.4	18

#	Article	IF	CITATIONS
235	Prediction of Compound Potency Changes in Matched Molecular Pairs Using Support Vector Regression. Journal of Chemical Information and Modeling, 2014, 54, 2654-2663.	2.5	18
236	Benzothiazolyl substituted iminothiazolidinones and benzamido-oxothiazolidines as potent and partly selective aldose reductase inhibitors. MedChemComm, 2014, 5, 1371-1380.	3.5	18
237	Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors. Organic and Biomolecular Chemistry, 2015, 13, 10310-10323.	1.5	18
238	Computational Method to Evaluate Progress in Lead Optimization. Journal of Medicinal Chemistry, 2018, 61, 10895-10900.	2.9	18
239	Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots. ACS Omega, 2019, 4, 1729-1737.	1.6	18
240	Prediction of Different Classes of Promiscuous and Nonpromiscuous Compounds Using Machine Learning and Nearest Neighbor Analysis. ACS Omega, 2019, 4, 6883-6890.	1.6	18
241	Advances in exploring activity cliffs. Journal of Computer-Aided Molecular Design, 2020, 34, 929-942.	1.3	18
242	Feature importance correlation from machine learning indicates functional relationships between proteins and similar compound binding characteristics. Scientific Reports, 2021, 11, 14245.	1.6	18
243	Monitoring drug promiscuity over time. F1000Research, 2014, 3, 218.	0.8	18
244	Exploring structure–selectivity relationships of biogenic amine GPCR antagonists using similarity searching and dynamic compound mapping. Molecular Diversity, 2008, 12, 25-40.	2.1	17
245	Similarity Searching using Compound Class‧pecific Combinations of Substructures Found in Randomly Generated Molecular Fragment Populations. ChemMedChem, 2008, 3, 67-73.	1.6	17
246	Molecular Mechanism-Based Network-like Similarity Graphs Reveal Relationships between Different Types of Receptor Ligands and Structural Changes that Determine Agonistic, Inverse-Agonistic, and Antagonistic Effects. Journal of Chemical Information and Modeling, 2011, 51, 1281-1286.	2.5	17
247	Identification of target family directed bioisosteric replacements. MedChemComm, 2011, 2, 601-606.	3.5	17
248	Searching for Coordinated Activity Cliffs Using Particle Swarm Optimization. Journal of Chemical Information and Modeling, 2012, 52, 927-934.	2.5	17
249	Fingerprint design and engineering strategies: rationalizing and improving similarity search performance. Future Medicinal Chemistry, 2012, 4, 1945-1959.	1.1	17
250	Introducing the LASSO Graph for Compound Data Set Representation and Structure–Activity Relationship Analysis. Journal of Medicinal Chemistry, 2012, 55, 5546-5553.	2.9	17
251	Method for the Evaluation of Structure–Activity Relationship Information Associated with Coordinated Activity Cliffs. Journal of Medicinal Chemistry, 2014, 57, 6553-6563.	2.9	17
252	Design of chemical space networks on the basis of Tversky similarity. Journal of Computer-Aided Molecular Design, 2016, 30, 1-12.	1.3	17

#	Article	IF	CITATIONS
253	Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space. RSC Advances, 2017, 7, 31069-31074.	1.7	17
254	Recent Progress in Structure-Based Evaluation of Compound Promiscuity. ACS Omega, 2019, 4, 2758-2765.	1.6	17
255	Identifying Promiscuous Compounds with Activity against Different Target Classes. Molecules, 2019, 24, 4185.	1.7	17
256	Monitoring drug promiscuity over time. F1000Research, 2014, 3, 218.	0.8	17
257	Utilizing Target–Ligand Interaction Information in Fingerprint Searching for Ligands of Related Targets. Chemical Biology and Drug Design, 2009, 74, 25-32.	1.5	16
258	Assessing the Confidence Level of Public Domain Compound Activity Data and the Impact of Alternative Potency Measurements on SAR Analysis. Journal of Chemical Information and Modeling, 2011, 51, 3131-3137.	2.5	16
259	Assessing the Growth of Bioactive Compounds and Scaffolds over Time: Implications for Lead Discovery and Scaffold Hopping. Journal of Chemical Information and Modeling, 2016, 56, 300-307.	2.5	16
260	Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective. Chemical Biology and Drug Design, 2017, 89, 834-845.	1.5	16
261	Rationalizing the Formation of Activity Cliffs in Different Compound Data Sets. ACS Omega, 2018, 3, 7736-7744.	1.6	16
262	Impact of Artificial Intelligence on Compound Discovery, Design, and Synthesis. ACS Omega, 2021, 6, 33293-33299.	1.6	16
263	A dual fingerprint-based metric for the design of focused compound libraries and analogs. Journal of Molecular Modeling, 2001, 7, 125-131.	0.8	15
264	Relevance of Feature Combinations for Similarity Searching Using General or Activity Class-Directed Molecular Fingerprints. Journal of Chemical Information and Modeling, 2009, 49, 561-570.	2.5	15
265	Threeâ€Dimensional Protein–Ligand Interaction Scaling of Twoâ€Dimensional Fingerprints. Chemical Biology and Drug Design, 2009, 74, 449-456.	1.5	15
266	Development of a Compound Class-Directed Similarity Coefficient That Accounts for Molecular Complexity Effects in Fingerprint Searching. Journal of Chemical Information and Modeling, 2009, 49, 1369-1376.	2.5	15
267	Shannon Entropy-Based Fingerprint Similarity Search Strategy. Journal of Chemical Information and Modeling, 2009, 49, 1687-1691.	2.5	15
268	Directed R-Group Combination Graph: A Methodology To Uncover Structure–Activity Relationship Patterns in a Series of Analogues. Journal of Medicinal Chemistry, 2012, 55, 1215-1226.	2.9	15
269	Identification and analysis of promiscuity cliffs formed by bioactive compounds and experimental implications. RSC Advances, 2017, 7, 58-66.	1.7	15
270	Modeling Tanimoto Similarity Value Distributions and Predicting Search Results. Molecular Informatics, 2017, 36, 1600131.	1.4	15

#	Article	IF	CITATIONS
271	Quantifying the Tendency of Therapeutic Target Proteins to Bind Promiscuous or Selective Compounds. PLoS ONE, 2015, 10, e0126838.	1.1	15
272	Measure, mine, model, and manipulate: the future for HTS and chemoinformatics?. Drug Discovery Today, 2006, 11, 863-865.	3.2	14
273	Analysis of Chemical Information Content Using Shannon Entropy. Reviews in Computational Chemistry, 2007, , 263-289.	1.5	14
274	Systematic Extraction of Structure–Activity Relationship Information from Biological Screening Data. ChemMedChem, 2009, 4, 1431-1438.	1.6	14
275	Exploring Target-Selectivity Patterns of Molecular Scaffolds. ACS Medicinal Chemistry Letters, 2010, 1, 54-58.	1.3	14
276	Application of Information—Theoretic Concepts in Chemoinformatics. Information (Switzerland), 2010, 1, 60-73.	1.7	14
277	Design and Evaluation of Bonded Atom Pair Descriptors. Journal of Chemical Information and Modeling, 2010, 50, 487-499.	2.5	14
278	Advances in 2D fingerprint similarity searching. Expert Opinion on Drug Discovery, 2010, 5, 529-542.	2.5	14
279	Comparison of two- and three-dimensional activity landscape representations for different compound data sets. MedChemComm, 2011, 2, 113-118.	3.5	14
280	Mapping of pharmacological space. Expert Opinion on Drug Discovery, 2011, 6, 1-7.	2.5	14
281	Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap. RSC Advances, 2012, 2, 3481.	1.7	14
282	Exploring Activity Cliffs from a Chemoinformatics Perspective. Molecular Informatics, 2014, 33, 438-442.	1.4	14
283	Chemical space visualization: transforming multidimensional chemical spaces into similarity-based molecular networks. Future Medicinal Chemistry, 2016, 8, 1769-1778.	1.1	14
284	One-pot synthesis of tetrazole-1,2,5,6-tetrahydronicotinonitriles and cholinesterase inhibition: Probing the plausible reaction mechanism via computational studies. Bioorganic Chemistry, 2016, 65, 38-47.	2.0	14
285	Structure-Promiscuity Relationship Puzzles—Extensively Assayed Analogs with Large Differences in Target Annotations. AAPS Journal, 2017, 19, 856-864.	2.2	14
286	Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens. ACS Omega, 2017, 2, 1463-1468.	1.6	14
287	Exploring Selectivity of Multikinase Inhibitors across the Human Kinome. ACS Omega, 2018, 3, 1147-1153.	1.6	14
288	Rationalizing Promiscuity Cliffs. ChemMedChem, 2018, 13, 490-494.	1.6	14

#	Article	IF	CITATIONS
289	Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. Molecular Pharmaceutics, 2020, 17, 4652-4666.	2.3	14
290	Assessing the information content of structural and protein–ligand interaction representations for the classification of kinase inhibitor binding modes via machine learning and active learning. Journal of Cheminformatics, 2020, 12, 36.	2.8	14
291	Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. Scientific Reports, 2021, 11, 7863.	1.6	14
292	Understanding chemoinformatics: a unifying approach. Drug Discovery Today, 2004, 9, 13-14.	3.2	13
293	RelACCSâ€FP: A Structural Minimalist Approach to Fingerprint Design. Chemical Biology and Drug Design, 2008, 72, 341-349.	1.5	13
294	Extraction of Structure-Activity Relationship Information from High-Throughput Screening Data. Current Medicinal Chemistry, 2009, 16, 4049-4057.	1.2	13
295	Combining Horizontal and Vertical Substructure Relationships in Scaffold Hierarchies for Activity Prediction. Journal of Chemical Information and Modeling, 2011, 51, 248-257.	2.5	13
296	Computational Medicinal Chemistry. Journal of Medicinal Chemistry, 2011, 54, 1-2.	2.9	13
297	Graph Mining for SAR Transfer Series. Journal of Chemical Information and Modeling, 2012, 52, 935-942.	2.5	13
298	Navigating High-Dimensional Activity Landscapes: Design and Application of the Ligand-Target Differentiation Map. Journal of Chemical Information and Modeling, 2012, 52, 1962-1969.	2.5	13
299	Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families. MedChemComm, 2013, 4, 1196.	3.5	13
300	Prediction of Individual Compounds Forming Activity Cliffs Using Emerging Chemical Patterns. Journal of Chemical Information and Modeling, 2013, 53, 3131-3139.	2.5	13
301	Introduction of a Methodology for Visualization and Graphical Interpretation of Bayesian Classification Models. Journal of Chemical Information and Modeling, 2014, 54, 2451-2468.	2.5	13
302	Many Approved Drugs Have Bioactive Analogs With Different Target Annotations. AAPS Journal, 2014, 16, 847-859.	2.2	13
303	Predicting bioactive conformations and binding modes of macrocycles. Journal of Computer-Aided Molecular Design, 2016, 30, 841-849.	1.3	13
304	Maximum common substructure-based Tversky index: an asymmetric hybrid similarity measure. Journal of Computer-Aided Molecular Design, 2016, 30, 523-531.	1.3	13
305	Improving the utility of molecular scaffolds for medicinal and computational chemistry. Future Medicinal Chemistry, 2018, 10, 1645-1648.	1.1	13
306	Duality of activity cliffs in drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 517-520.	2.5	13

#	Article	IF	CITATIONS
307	Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. Biomolecules, 2020, 10, 1605.	1.8	13
308	Evolution of assay interference concepts in drug discovery. Expert Opinion on Drug Discovery, 2021, 16, 719-721.	2.5	13
309	Activity artifacts in drug discovery and different facets of compound promiscuity. F1000Research, 2014, 3, 233.	0.8	13
310	Random Reduction in Fingerprint Bit Density Improves Compound Recall in Search Calculations Using Complex Reference Molecules. Chemical Biology and Drug Design, 2008, 71, 511-517.	1.5	12
311	Molecular Formal Concept Analysis for Compound Selectivity Profiling in Biologically Annotated Databases. Journal of Chemical Information and Modeling, 2009, 49, 1359-1368.	2.5	12
312	Advanced Fingerprint Methods for Similarity Searching: Balancing Molecular Complexity Effects. Combinatorial Chemistry and High Throughput Screening, 2010, 13, 220-228.	0.6	12
313	Structural and Potency Relationships between Scaffolds of Compounds Active against Human Targets. ChemMedChem, 2010, 5, 1681-1685.	1.6	12
314	Representation of Multiâ€Target Activity Landscapes Through Target Pairâ€Based Compound Encoding in Selfâ€Organizing Maps. Chemical Biology and Drug Design, 2011, 78, 778-786.	1.5	12
315	Quantifying the Fingerprint Descriptor Dependence of Structure–Activity Relationship Information on a Large Scale. Journal of Chemical Information and Modeling, 2013, 53, 2275-2281.	2.5	12
316	Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds. European Journal of Medicinal Chemistry, 2014, 76, 427-434.	2.6	12
317	Extraction of SAR information from activity cliff clusters via matching molecular series. European Journal of Medicinal Chemistry, 2014, 87, 454-460.	2.6	12
318	Introducing the â€~active search' method for iterative virtual screening. Journal of Computer-Aided Molecular Design, 2015, 29, 305-314.	1.3	12
319	Activity cliff clusters as a source of structure–activity relationship information. Expert Opinion on Drug Discovery, 2015, 10, 441-447.	2.5	12
320	Monitoring global growth of activity cliff information over time and assessing activity cliff frequencies and distributions. Future Medicinal Chemistry, 2015, 7, 1565-1579.	1.1	12
321	Binding mode similarity measures for ranking of docking poses: a case study on the adenosine A2A receptor. Journal of Computer-Aided Molecular Design, 2016, 30, 447-456.	1.3	12
322	A Fluorescent‣abeled Phosphono Bisbenzguanidine As an Activityâ€Based Probe for Matriptase. Chemistry - A European Journal, 2017, 23, 5205-5209.	1.7	12
323	Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases. Molecules, 2017, 22, 730.	1.7	12
324	Computational method for estimating progression saturation of analog series. RSC Advances, 2018, 8, 5484-5492.	1.7	12

#	Article	IF	CITATIONS
325	Reconciling Selectivity Trends from a Comprehensive Kinase Inhibitor Profiling Campaign with Known Activity Data. ACS Omega, 2018, 3, 3113-3119.	1.6	12
326	Introducing a new category of activity cliffs with chemical modifications at multiple sites and rationalizing contributions of individual substitutions. Bioorganic and Medicinal Chemistry, 2019, 27, 3605-3612.	1.4	12
327	Second-generation activity cliffs identified on the basis of target set-dependent potency difference criteria. Future Medicinal Chemistry, 2019, 11, 379-394.	1.1	12
328	Methods for Computerâ€Aided Chemical Biology. Part 4: Selectivity Searching for Ion Channel Ligands and Mapping of Molecular Fragments as Selectivity Markers. Chemical Biology and Drug Design, 2009, 73, 273-282.	1.5	11
329	Application of Support Vector Machine-Based Ranking Strategies to Search for Target-Selective Compounds. Methods in Molecular Biology, 2011, 672, 517-530.	0.4	11
330	Activity cliffs in PubChem confirmatory bioassays taking inactive compounds into account. Journal of Computer-Aided Molecular Design, 2013, 27, 115-124.	1.3	11
331	Systematic mining of analog series with related core structures in multi-target activity space. Journal of Computer-Aided Molecular Design, 2013, 27, 665-674.	1.3	11
332	Evolution of the activity cliff concept for structure–activity relationship analysis and drug discovery. Future Medicinal Chemistry, 2014, 6, 1545-1549.	1.1	11
333	Syntheses, Cholinesterases Inhibition, and Molecular Docking Studies of Pyrido[2,3â€ <i>b</i> ]pyrazine Derivatives. Chemical Biology and Drug Design, 2015, 86, 1115-1120.	1.5	11
334	Identification and analysis of the currently available high-confidence three-dimensional activity cliffs. RSC Advances, 2015, 5, 43660-43668.	1.7	11
335	Extending accessible chemical space for the identification of novel leads. Expert Opinion on Drug Discovery, 2016, 11, 825-829.	2.5	11
336	Recent developments in SAR visualization. MedChemComm, 2016, 7, 1045-1055.	3.5	11
337	Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structureâ€Based Design of Inhibitors for Trypsinâ€Like Serine Proteases. Chemistry - A European Journal, 2016, 22, 610-625.	1.7	11
338	From Qualitative to Quantitative Analysis of Activity and Property Landscapes. Journal of Chemical Information and Modeling, 2020, 60, 5873-5880.	2.5	11
339	Activity landscape image analysis using convolutional neural networks. Journal of Cheminformatics, 2020, 12, 34.	2.8	11
340	Deep SAR matrix: SAR matrix expansion for advanced analog design using deep learning architectures. Future Drug Discovery, 2020, 2, .	0.8	11
341	Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents. PLoS Neglected Tropical Diseases, 2020, 14, e0007755.	1.3	11
342	Prediction of activity cliffs on the basis of images using convolutional neural networks. Journal of Computer-Aided Molecular Design, 2021, 35, 1157-1164.	1.3	11

#	Article	IF	CITATIONS
343	ccbmlib – a Python package for modeling Tanimoto similarity value distributions. F1000Research, 2020, 9, 100.	0.8	11
344	Explainable machine learning predictions of dual-target compounds reveal characteristic structural features. Scientific Reports, 2021, 11, 21594.	1.6	11
345	Filtering and Counting of Extended Connectivity Fingerprint Features Maximizes Compound Recall and the Structural Diversity of Hits. Chemical Biology and Drug Design, 2009, 74, 92-98.	1.5	10
346	Rendering Conventional Molecular Fingerprints for Virtual Screening Independent of Molecular Complexity and Size Effects. ChemMedChem, 2010, 5, 859-868.	1.6	10
347	Exploring SAR Continuity in the Vicinity of Activity Cliffs. Chemical Biology and Drug Design, 2012, 79, 22-29.	1.5	10
348	Conditional Probabilities of Activity Landscape Features for Individual Compounds. Journal of Chemical Information and Modeling, 2013, 53, 1602-1612.	2.5	10
349	Similarity Searching for Potent Compounds Using Feature Selection. Journal of Chemical Information and Modeling, 2013, 53, 1613-1619.	2.5	10
350	Activity profile relationships between structurally similar promiscuous compounds. European Journal of Medicinal Chemistry, 2013, 69, 393-398.	2.6	10
351	SAR Transfer across Different Targets. Journal of Chemical Information and Modeling, 2013, 53, 1589-1594.	2.5	10
352	AnalogExplorer: A New Method for Graphical Analysis of Analog Series and Associated Structure–Activity Relationship Information. Journal of Medicinal Chemistry, 2014, 57, 9184-9194.	2.9	10
353	Combining Similarity Searching and Network Analysis for the Identification of Active Compounds. ACS Omega, 2018, 3, 3768-3777.	1.6	10
354	Extracting Compound Profiling Matrices from Screening Data. ACS Omega, 2018, 3, 4706-4712.	1.6	10
355	Foundations of data-driven medicinal chemistry. Future Science OA, 2018, 4, FSO320.	0.9	10
356	Introducing a new category of activity cliffs combining different compound similarity criteria. RSC Medicinal Chemistry, 2020, 11, 132-141.	1.7	10
357	Evaluation of multi-target deep neural network models for compound potency prediction under increasingly challenging test conditions. Journal of Computer-Aided Molecular Design, 2021, 35, 285-295.	1.3	10
358	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected?. Journal of Medicinal Chemistry, 2022, 65, 6973-6974.	2.9	10
359	Target Family-Directed Exploration of Scaffolds with Different SAR Profiles. Journal of Chemical Information and Modeling, 2011, 51, 3138-3148.	2.5	9
360	Mechanism-based bipartite matching molecular series graphs to identify structural modifications of receptor ligands that lead to mechanism hopping. MedChemComm, 2012, 3, 441.	3.5	9

#	Article	IF	CITATIONS
361	Large-scale SAR analysis. Drug Discovery Today: Technologies, 2013, 10, e419-e426.	4.0	9
362	Extension of three-dimensional activity cliff information through systematic mapping of active analogs. RSC Advances, 2015, 5, 43006-43015.	1.7	9
363	Systematic assessment of coordinated activity cliffs formed by kinase inhibitors and detailed characterization of activity cliff clusters and associated SAR information. European Journal of Medicinal Chemistry, 2015, 90, 414-427.	2.6	9
364	Advancing the Kinase Field: New Targets and Second Generation Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 1-1.	2.9	9
365	Privileged Structural Motif Detection and Analysis Using Generative Topographic Maps. Journal of Chemical Information and Modeling, 2017, 57, 1218-1232.	2.5	9
366	Compound Data Mining for Drug Discovery. Methods in Molecular Biology, 2017, 1526, 247-256.	0.4	9
367	Computational Assessment of Chemical Saturation of Analogue Series under Varying Conditions. ACS Omega, 2018, 3, 15799-15808.	1.6	9
368	Data-Driven Exploration of Selectivity and Off-Target Activities of Designated Chemical Probes. Molecules, 2018, 23, 2434.	1.7	9
369	Three-Dimensional Activity Landscape Models of Different Design and Their Application to Compound Mapping and Potency Prediction. Journal of Chemical Information and Modeling, 2019, 59, 993-1004.	2.5	9
370	Prediction of an MMP-1 inhibitor activity cliff using the SAR matrix approach and its experimental validation. Scientific Reports, 2020, 10, 14710.	1.6	9
371	The SAR Matrix Method and an Artificially Intelligent Variant for the Identification and Structural Organization of Analog Series, SAR Analysis, and Compound Design. Molecular Informatics, 2020, 39, e2000045.	1.4	9
372	Follow-up: Prospective compound design using the â€~SAR Matrix' method and matrix-derived conditional probabilities of activity. F1000Research, 0, 4, 75.	0.8	9
373	New Horizons in Drug Discovery - Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects. Journal of Medicinal Chemistry, 2022, 65, 891-892.	2.9	9
374	Design and Exploration of Target-Selective Chemical Space Representations. Journal of Chemical Information and Modeling, 2008, 48, 1389-1395.	2.5	8
375	Random Molecular Fragment Methods in Computational Medicinal Chemistry. Current Medicinal Chemistry, 2008, 15, 2108-2121.	1.2	8
376	Computational screening for membrane-directed inhibitors of mast cell activation. European Journal of Medicinal Chemistry, 2010, 45, 2700-2704.	2.6	8
377	Potencyâ€Directed Similarity Searching Using Support Vector Machines. Chemical Biology and Drug Design, 2011, 77, 30-38.	1.5	8
378	Identification of Multitarget Activity Ridges in High-Dimensional Bioactivity Spaces. Journal of Chemical Information and Modeling, 2012, 52, 2579-2586.	2.5	8

#	Article	IF	CITATIONS
379	Multiobjective Particle Swarm Optimization: Automated Identification of Structure–Activity Relationship-Informative Compounds with Favorable Physicochemical Property Distributions. Journal of Chemical Information and Modeling, 2012, 52, 2848-2855.	2.5	8
380	Evaluation of molecular model-based discovery of ecto-5′-nucleotidase inhibitors on the basis of X-ray structures. Bioorganic and Medicinal Chemistry, 2013, 21, 6616-6622.	1.4	8
381	Introduction of Target Cliffs as a Concept To Identify and Describe Complex Molecular Selectivity Patterns. Journal of Chemical Information and Modeling, 2013, 53, 545-552.	2.5	8
382	Improving data mining strategies for drug design. Future Medicinal Chemistry, 2014, 6, 255-257.	1.1	8
383	Identification of Interaction Hot Spots in Structures of Drug Targets on the Basis of Threeâ€Đimensional Activity Cliff Information. Chemical Biology and Drug Design, 2015, 86, 1458-1465.	1.5	8
384	Analyzing Promiscuity at the Level of Active Compounds and Targets. Molecular Informatics, 2016, 35, 583-587.	1.4	8
385	Classification of matching molecular series on the basis of SAR phenotypes and structural relationships. MedChemComm, 2016, 7, 237-246.	3.5	8
386	Design of a tripartite network for the prediction of drug targets. Journal of Computer-Aided Molecular Design, 2018, 32, 321-330.	1.3	8
387	Redundancy in two major compound databases. Drug Discovery Today, 2018, 23, 1183-1186.	3.2	8
388	Collection of analog series-based scaffolds from public compound sources. Future Science OA, 2018, 4, FSO287.	0.9	8
389	A general approach for retrosynthetic molecular core analysis. Journal of Cheminformatics, 2019, 11, 61.	2.8	8
390	Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome. Journal of Computer-Aided Molecular Design, 2019, 33, 559-572.	1.3	8
391	Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome. Journal of Computer-Aided Molecular Design, 2020, 34, 1-10.	1.3	8
392	Predicting Isoform-Selective Carbonic Anhydrase Inhibitors via Machine Learning and Rationalizing Structural Features Important for Selectivity. ACS Omega, 2021, 6, 4080-4089.	1.6	8
393	Fine-tuning of a generative neural network for designing multi-target compounds. Journal of Computer-Aided Molecular Design, 2022, 36, 363-371.	1.3	8
394	Exploring sets of molecules from patents and relationships to other active compounds in chemical space networks. Journal of Computer-Aided Molecular Design, 2017, 31, 779-788.	1.3	8
395	Promiscuity progression of bioactive compounds over time. F1000Research, 2015, 4, 118.	0.8	8
396	Computational design of new molecular scaffolds for medicinal chemistry, part II: generalization of analog series-based scaffolds. Future Science OA, 2018, 4, FSO267.	0.9	8

#	Article	IF	CITATIONS
397	Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling. Molecules, 2022, 27, 570.	1.7	8
398	Deep Machine Learning for Computer-Aided Drug Design. Frontiers in Drug Discovery, 2022, 2, .	1.1	8
399	Artificial intelligence in interdisciplinary life science and drug discovery research. Future Science OA, 2022, 8, FSO792.	0.9	8
400	Machine Learning in Chemoinformatics and Medicinal Chemistry. Annual Review of Biomedical Data Science, 2022, 5, 43-65.	2.8	8
401	Exploring Peptide-likeness of Active Molecules Using 2D Fingerprint Methods. Journal of Chemical Information and Modeling, 2007, 47, 1366-1378.	2.5	7
402	Hit Expansion through Computational Selectivity Searching. ChemMedChem, 2009, 4, 52-54.	1.6	7
403	Predicting the Performance of Fingerprint Similarity Searching. Methods in Molecular Biology, 2010, 672, 159-173.	0.4	7
404	Computational chemistry in pharmaceutical research: at the crossroads. Journal of Computer-Aided Molecular Design, 2012, 26, 11-12.	1.3	7
405	Compound Pathway Model To Capture SAR Progression: Comparison of Activity Cliff-Dependent and -Independent Pathways. Journal of Chemical Information and Modeling, 2013, 53, 1067-1072.	2.5	7
406	Systematic Identification of Matching Molecular Series and Mapping of Screening Hits. Molecular Informatics, 2014, 33, 257-263.	1.4	7
407	Evaluation of bisbenzamidines as inhibitors for matriptase-2. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3741-3745.	1.0	7
408	Large-Scale Comparison of Alternative Similarity Search Strategies with Varying Chemical Information Contents. ACS Omega, 2019, 4, 15304-15311.	1.6	7
409	Systematic identification of target set-dependent activity cliffs. Future Science OA, 2019, 5, FSO363.	0.9	7
410	Exploring Alternative Strategies for the Identification of Potent Compounds Using Support Vector Machine and Regression Modeling. Journal of Chemical Information and Modeling, 2019, 59, 983-992.	2.5	7
411	DeepCOMO: from structure-activity relationship diagnostics to generative molecular design using the compound optimization monitor methodology. Journal of Computer-Aided Molecular Design, 2020, 34, 1207-1218.	1.3	7
412	Global Assessment of Substituents on the Basis of Analogue Series. Journal of Medicinal Chemistry, 2020, 63, 15013-15020.	2.9	7
413	Compounds with multitarget activity: structure-based analysis and machine learning. Future Drug Discovery, 2020, 2, .	0.8	7
414	X-ray Structure-Based Chemoinformatic Analysis Identifies Promiscuous Ligands Binding to Proteins from Different Classes with Varying Shapes. International Journal of Molecular Sciences, 2020, 21, 3782.	1.8	7

#	Article	IF	CITATIONS
415	Exploring differential evolution for inverse QSAR analysis. F1000Research, 2017, 6, 1285.	0.8	7
416	Follow-up: Prospective compound design using the â€~SAR Matrix' method and matrix-derived conditional probabilities of activity. F1000Research, 2015, 4, 75.	0.8	7
417	Analyzing compound activity records and promiscuity degrees in light of publication statistics. F1000Research, 2016, 5, 1227.	0.8	7
418	Computational Analysis of Activity and Selectivity Cliffs. Methods in Molecular Biology, 2011, 672, 119-132.	0.4	6
419	Design of a Three-Dimensional Multitarget Activity Landscape. Journal of Chemical Information and Modeling, 2012, 52, 2876-2883.	2.5	6
420	Progress in Computational Medicinal Chemistry. Journal of Medicinal Chemistry, 2012, 55, 3593-3594.	2.9	6
421	Activity Cliff Networks for Medicinal Chemistry. Drug Development Research, 2014, 75, 291-298.	1.4	6
422	Modeling of Compound Profiling Experiments Using Support Vector Machines. Chemical Biology and Drug Design, 2014, 84, 75-85.	1.5	6
423	Structural and Modeling Studies on ecto-5'-nucleotidase Aiding in Inhibitor Design. Mini-Reviews in Medicinal Chemistry, 2015, 15, 34-40.	1.1	6
424	Pushing the boundaries of computational approaches: special focus issue on computational chemistry and computer-aided drug discovery. Future Medicinal Chemistry, 2015, 7, 2415-2417.	1.1	6
425	Structural and Activity Profile Relationships Between Drug Scaffolds. AAPS Journal, 2015, 17, 609-619.	2.2	6
426	Systematic Assessment of Molecular Selectivity at the Level of Targets, Bioactive Compounds, and Structural Analogues. ChemMedChem, 2016, 11, 1362-1370.	1.6	6
427	Compound Ranking Based on Fuzzy Three-Dimensional Similarity Improves the Performance of Docking into Homology Models of G-Protein-Coupled Receptors. ACS Omega, 2017, 2, 2583-2592.	1.6	6
428	Dark chemical matter in public screening assays and derivation of target hypotheses. MedChemComm, 2017, 8, 2100-2104.	3.5	6
429	Integrating computational lead optimization diagnostics with analog design and candidate selection. Future Science OA, 2020, 6, FSO451.	0.9	6
430	Prediction of Promiscuity Cliffs Using Machine Learning. Molecular Informatics, 2021, 40, 2000196.	1.4	6
431	Systematic comparison of competitive and allosteric kinase inhibitors reveals common structural characteristics. European Journal of Medicinal Chemistry, 2021, 214, 113206.	2.6	6
432	Structural characteristics of compounds with multitarget activity. Future Drug Discovery, 2021, 3, .	0.8	6

#	Article	IF	CITATIONS
433	Development of curcumin-based amyloid β aggregation inhibitors for Alzheimer's disease using the SAR matrix approach. Bioorganic and Medicinal Chemistry, 2021, 46, 116357.	1.4	6
434	Systematic mapping of R-group space enables the generation of an R-group replacement system for medicinal chemistry. European Journal of Medicinal Chemistry, 2021, 225, 113771.	2.6	6
435	Analysis of a High-Throughput Screening Data Set Using Potency-Scaled Molecular Similarity Algorithms. Journal of Chemical Information and Modeling, 2007, 47, 367-375.	2.5	5
436	Predicting the similarity search performance of fingerprints and their combination with molecular property descriptors using probabilistic and information theoretic modeling. Statistical Analysis and Data Mining, 2009, 2, 123-134.	1.4	5
437	Rationalizing the Role of SAR Tolerance for Ligand-Based Virtual Screening. Journal of Chemical Information and Modeling, 2011, 51, 837-842.	2.5	5
438	Molecular Test Systems for Computational Selectivity Studies and Systematic Analysis of Compound Selectivity Profiles. Methods in Molecular Biology, 2011, 672, 503-515.	0.4	5
439	Formation of Activity Cliffs Is Accompanied by Systematic Increases in Ligand Efficiency from Lowly to Highly Potent Compounds. AAPS Journal, 2014, 16, 335-341.	2.2	5
440	Hierarchical Analysis of Bioactive Matched Molecular Pairs, Encoded Chemical Transformations, and Associated Substructures. Molecular Informatics, 2016, 35, 483-488.	1.4	5
441	Tracing compound pathways using chemical space networks. MedChemComm, 2017, 8, 376-384.	3.5	5
442	From bird's eye views to molecular communities: two-layered visualization of structure–activity relationships in large compound data sets. Journal of Computer-Aided Molecular Design, 2017, 31, 961-977.	1.3	5
443	Data analytics and deep learning in medicinal chemistry. Future Medicinal Chemistry, 2018, 10, 1541-1543.	1.1	5
444	Method for Systematic Analogue Search Using the Mega SAR Matrix Database. Journal of Chemical Information and Modeling, 2019, 59, 3727-3734.	2.5	5
445	Computational chemical biology on the rise. Future Medicinal Chemistry, 2019, 11, 1-3.	1.1	5
446	Compound optimization monitor (COMO) method for computational evaluation of progress in medicinal chemistry projects. Future Drug Discovery, 2019, 1, FDD15.	0.8	5
447	Activity cliffs produced by single-atom modification of active compounds: Systematic identification and rationalization based on X-ray structures. European Journal of Medicinal Chemistry, 2020, 207, 112846.	2.6	5
448	Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome. Data in Brief, 2020, 32, 106189.	0.5	5
449	Computational method for the identification of third generation activity cliffs. MethodsX, 2020, 7, 100793.	0.7	5
450	Systematic Exploration of Activity Cliffs Containing Privileged Substructures. Molecular Pharmaceutics, 2020, 17, 979-989.	2.3	5

#	Article	IF	CITATIONS
451	Introducing the metacore concept for multi-target ligand design. RSC Medicinal Chemistry, 2021, 12, 628-635.	1.7	5
452	Adapting the DeepSARM approach for dual-target ligand design. Journal of Computer-Aided Molecular Design, 2021, 35, 587-600.	1.3	5
453	R-group replacement database for medicinal chemistry. Future Science OA, 2021, 7, FSO742.	0.9	5
454	Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity. F1000Research, 2017, 6, 1505.	0.8	5
455	Matched molecular pair-based data sets for computer-aided medicinal chemistry. F1000Research, 2014, 3, 36.	0.8	5
456	Matched molecular pair-based data sets for computer-aided medicinal chemistry. F1000Research, 2014, 3, 36.	0.8	5
457	Entering new publication territory in chemoinformatics and chemical information science. F1000Research, 2015, 4, 35.	0.8	5
458	ccbmlib – a Python package for modeling Tanimoto similarity value distributions. F1000Research, 2020, 9, 100.	0.8	5
459	Introducing a Chemically Intuitive Core-Substituent Fingerprint Designed to Explore Structural Requirements for Effective Similarity Searching and Machine Learning. Molecules, 2022, 27, 2331.	1.7	5
460	Differentiating Inhibitors of Closely Related Protein Kinases with Single- or Multi-Target Activity via Explainable Machine Learning and Feature Analysis. Biomolecules, 2022, 12, 557.	1.8	5
461	DeepAS – Chemical language model for the extension of active analogue series. Bioorganic and Medicinal Chemistry, 2022, 66, 116808.	1.4	5
462	Distribution of randomly generated activity class characteristic substructures in diverse active and database compounds. Molecular Diversity, 2008, 12, 77-83.	2.1	4
463	Rationalization of the Performance and Target Dependence of Similarity Searching Incorporating Proteinâ ''Ligand Interaction Information. Journal of Chemical Information and Modeling, 2010, 50, 1042-1052.	2.5	4
464	Extraction of Discontinuous Structure–Activity Relationships from Compound Data Sets through Particle Swarm Optimization. Journal of Chemical Information and Modeling, 2011, 51, 1545-1551.	2.5	4
465	Activity Profile Sequences: a Concept to Account for the Progression of Compound Activity in Target Space and to Extract SAR Information from Analogue Series with Multiple Target Annotations. ChemMedChem, 2011, 6, 2150-2154.	1.6	4
466	Lipid-like sulfoxides and amine oxides as inhibitors of mast cell activation. European Journal of Medicinal Chemistry, 2011, 46, 2147-2151.	2.6	4
467	Chemoinformatics: Recent advances at the interfaces between computer and chemical information sciences, chemistry, and drug discovery. Bioorganic and Medicinal Chemistry, 2012, 20, 5316.	1.4	4
468	Systematic assessment of scaffold distances in ChEMBL: prioritization of compound data sets for scaffold hopping analysis in virtual screening. Journal of Computer-Aided Molecular Design, 2012, 26, 1101-1109.	1.3	4

#	Article	IF	CITATIONS
469	Systematic assessment of scaffold hopping versus activity cliff formation across bioactive compound classes following a molecular hierarchy. Bioorganic and Medicinal Chemistry, 2015, 23, 3183-3191.	1.4	4
470	Hit Expansion from Screening Data Based upon Conditional Probabilities of Activity Derived from SAR Matrices. Molecular Informatics, 2015, 34, 134-146.	1.4	4
471	Systematic assessment of analog relationships between bioactive compounds and promiscuity of analog sets. MedChemComm, 2016, 7, 230-236.	3.5	4
472	Identifying relationships between unrelated pharmaceutical target proteins on the basis of shared active compounds. Future Science OA, 2017, 3, FSO212.	0.9	4
473	Exploring differential evolution for inverse QSAR analysis. F1000Research, 2017, 6, 1285.	0.8	4
474	Evaluation of different virtual screening strategies on the basis of compound sets with characteristic core distributions and dissimilarity relationships. Journal of Computer-Aided Molecular Design, 2019, 33, 729-743.	1.3	4
475	New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7921-7922.	2.9	4
476	N-Sulfonyl dipeptide nitriles as inhibitors of human cathepsin S: In silico design, synthesis and biochemical characterization. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127420.	1.0	4
477	Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. European Journal of Medicinal Chemistry, 2020, 204, 112641.	2.6	4
478	Computational Method for Structure-Based Analysis of SAR Transfer. Journal of Medicinal Chemistry, 2020, 63, 1388-1396.	2.9	4
479	From SAR Diagnostics to Compound Design: Development Chronology of the Compound Optimization Monitor (COMO) Method. Molecular Informatics, 2020, 39, 2000046.	1.4	4
480	Data set of competitive and allosteric protein kinase inhibitors confirmed by X-ray crystallography. Data in Brief, 2021, 35, 106816.	0.5	4
481	Compound dataset and custom code for deep generative multi-target compound design. Future Science OA, 2021, 7, FSO715.	0.9	4
482	Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity. F1000Research, 2017, 6, 1505.	0.8	4
483	Compound data sets and software tools for chemoinformatics and medicinal chemistry applications: update and data transfer. F1000Research, 2014, 3, 69.	0.8	4
484	Analyzing compound activity records and promiscuity degrees in light of publication statistics. F1000Research, 2016, 5, 1227.	0.8	4
485	Inhibitor bias in luciferase-based luminescence assays. Future Science OA, 2020, 6, FSO594.	0.9	4
486	Fragment Formal Concept Analysis Accurately Classifies Compounds with Closely Related Biological Activities. ChemMedChem, 2009, 4, 1174-1181.	1.6	3

#	Article	IF	CITATIONS
487	Methods for Computerâ€Aided Chemical Biology. Part 5: Rationalizing the Selectivity of Cathepsin Inhibitors on the Basis of Molecular Fragments and Topological Feature Distributions. Chemical Biology and Drug Design, 2009, 74, 129-141.	1.5	3
488	Inhibitors of Cathepsins K and S Identified Using the DynaMAD Virtual Screening Algorithm. ChemMedChem, 2010, 5, 61-64.	1.6	3
489	Adaptation of formal concept analysis for the systematic exploration of structure-activity and structure-selectivity relationships. Journal of Cheminformatics, 2010, 2, .	2.8	3
490	Rationalizing Structure and Target Relationships between Current Drugs. AAPS Journal, 2012, 14, 764-771.	2.2	3
491	Computational Chemical Biology: Identification of Small Molecular Probes that Discriminate between Members of Target Protein Families. Chemical Biology and Drug Design, 2012, 79, 369-375.	1.5	3
492	Compound Optimization through Data Set-Dependent Chemical Transformations. Journal of Chemical Information and Modeling, 2013, 53, 1263-1271.	2.5	3
493	Active Site Mapping of Human Cathepsinâ€F with Dipeptide Nitrile Inhibitors. ChemMedChem, 2015, 10, 1365-1377.	1.6	3
494	Structural diversity and potency range distribution of scaffolds from compounds active against current pharmaceutical targets. Future Medicinal Chemistry, 2015, 7, 111-122.	1.1	3
495	Computational chemistry and computer-aided drug discovery: Part I. Future Medicinal Chemistry, 2016, 8, 1705-1706.	1.1	3
496	Computational chemistry and computer-aided drug discovery: Part II. Future Medicinal Chemistry, 2016, 8, 1799-1800.	1.1	3
497	Systematic analysis of structural and activity relationships between conventional hierarchical and analog series-based scaffolds. RSC Advances, 2017, 7, 18718-18723.	1.7	3
498	From activity cliffs to promiscuity cliffs. Future Science OA, 2017, 3, FSO227.	0.9	3
499	Identification of 4â€arylâ€1 <i>H</i> â€pyrrole[2,3â€b]pyridine derivatives for the development of new Bâ€Raf inhibitors. Chemical Biology and Drug Design, 2018, 92, 1382-1386.	1.5	3
500	A Hybrid Virtual Screening Protocol Based on Binding Mode Similarity. Methods in Molecular Biology, 2018, 1824, 165-175.	0.4	3
501	Data structures for compound promiscuity analysis: promiscuity cliffs, pathways and promiscuity hubs formed by inhibitors of the human kinome. Future Science OA, 2019, 5, FSO404.	0.9	3
502	The Future Is Now: Artificial Intelligence in Drug Discovery. Journal of Medicinal Chemistry, 2019, 62, 5249-5249.	2.9	3
503	Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. European Journal of Medicinal Chemistry, 2020, 187, 112004.	2.6	3
504	Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 41, 116226.	1.4	3

#	Article	IF	CITATIONS
505	Chemistry-centric explanation of machine learning models. Artificial Intelligence in the Life Sciences, 2021, 1, 100009.	1.6	3
506	AnalogExplorer2 – Stereochemistry sensitive graphical analysis of large analog series. F1000Research, 2015, 4, 1031.	0.8	3
507	On the evolving open peer review culture for chemical information science. F1000Research, 2015, 4, 1350.	0.8	3
508	A Novel Descriptor Histogram Filtering Method for Database Mining and the Identification of Active Molecules. Letters in Drug Design and Discovery, 2007, 4, 286-292.	0.4	3
509	Freely available compound data sets and software tools for chemoinformatics and computational medicinal chemistry applications. F1000Research, 2012, 1, 11.	0.8	3
510	Computational method for the systematic alignment of analogue series with structure-activity relationship transfer potential across different targets. European Journal of Medicinal Chemistry, 2022, 239, 114558.	2.6	3
511	Potency-directed similarity searching using support vector machines. Journal of Cheminformatics, 2012, 4, .	2.8	2
512	Molecular crime scene investigation – dusting for fingerprints. Drug Discovery Today: Technologies, 2013, 10, e491-e498.	4.0	2
513	Searching for Closely Related Ligands with Different Mechanisms of Action Using Machine Learning and Mapping Algorithms. Journal of Chemical Information and Modeling, 2013, 53, 2252-2274.	2.5	2
514	Visualization of Activity Landscapes and Chemogenomics Data. Molecular Informatics, 2013, 32, 954-963.	1.4	2
515	Large-Scale Assessment of Activity Landscape Feature Probabilities of Bioactive Compounds. Journal of Chemical Information and Modeling, 2014, 54, 442-450.	2.5	2
516	Identification of Orthologous Target Pairs with SharedÂActive Compounds and Comparison of Organismâ€specific Activity Patterns. Chemical Biology and Drug Design, 2015, 86, 1105-1114.	1.5	2
517	Visualization of multi-property landscapes for compound selection and optimization. Journal of Computer-Aided Molecular Design, 2015, 29, 695-705.	1.3	2
518	Systematic design of analogs of active compounds covering more than 1000 targets. MedChemComm, 2016, 7, 859-863.	3.5	2
519	Is scaffold hopping a reliable indicator for the ability of computational methods to identify structurally diverse active compounds?. Journal of Computer-Aided Molecular Design, 2017, 31, 603-608.	1.3	2
520	Exploring Structural Relationships between Bioactive and Commercial Chemical Space and Developing Target Hypotheses for Compound Acquisition. ACS Omega, 2017, 2, 7760-7766.	1.6	2
521	Evaluation of Kinase Inhibitor Selectivity Using Cellâ€based Profiling Data. Molecular Informatics, 2018, 37, e1800024.	1.4	2
522	Series of screening compounds with high hit rates for the exploration of multi-target activities and assay interference. Future Science OA, 2018, 4, FSO279.	0.9	2

#	Article	IF	CITATIONS
523	SAR Matrix Method for Large-Scale Analysis of Compound Structure–Activity Relationships and Exploration of Multitarget Activity Spaces. Methods in Molecular Biology, 2018, 1825, 339-352.	0.4	2
524	Exploring ensembles of bioactive or virtual analogs of X-ray ligands for shape similarity searching. Journal of Computer-Aided Molecular Design, 2018, 32, 759-767.	1.3	2
525	Forward-looking perspective on publishing in drug discovery. Future Drug Discovery, 2019, 1, FDD2.	0.8	2
526	Exploring structure-promiscuity relationships using dual-site promiscuity cliffs and corresponding single-site analogs. Bioorganic and Medicinal Chemistry, 2020, 28, 115238.	1.4	2
527	Quantitative Comparison of Three-Dimensional Activity Landscapes of Compound Data Sets Based upon Topological Features. ACS Omega, 2020, 5, 24111-24117.	1.6	2
528	Increasing the public activity cliff knowledge base with new categories of activity cliffs. Future Science OA, 2020, 6, FSO472.	0.9	2
529	Biological Activity Profiles of Multitarget Ligands from X-ray Structures. Molecules, 2020, 25, 794.	1.7	2
530	Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays. Future Science OA, 2021, 7, FSO685.	0.9	2
531	Design of chemical space networks incorporating compound distance relationships. F1000Research, 2016, 5, 2634.	0.8	2
532	Repositioning the Chemical Information Science Gateway. F1000Research, 2019, 8, 976.	0.8	2
533	Data-Driven Analysis of Fluorination of Ligands of Aminergic G Protein Coupled Receptors. Biomolecules, 2021, 11, 1647.	1.8	2
534	Learning functional group chemistry from molecular images leads to accurate prediction of activity cliffs. Artificial Intelligence in the Life Sciences, 2021, 1, 100022.	1.6	2
535	From traditional to data-driven medicinal chemistry: A case study. Drug Discovery Today, 2022, 27, 2065-2070.	3.2	2
536	Explainable machine learning for medicinal chemistry: exploring multi-target compounds. Future Medicinal Chemistry, 2022, 14, 1171-1173.	1.1	2
537	Iterative Shannon Entropy – a Methodology to Quantify the Information Content of Value Range Dependent Data Distributions. Application to Descriptor and Compound Selectivity Profiling. Molecular Informatics, 2010, 29, 432-440.	1.4	1
538	Design of multi-target activity landscapes that capture hierarchical activity cliff distributions. Journal of Cheminformatics, 2012, 4, .	2.8	1
539	Design of an activity landscape view taking compound-based feature probabilities into account. Journal of Computer-Aided Molecular Design, 2014, 28, 919-926.	1.3	1
540	Method for Systematic Assessment of Chemical Changes in Molecular Scaffolds with Conserved Topology and Application to the Analysis of Scaffoldâ€Activity Relationships. Molecular Informatics, 2015, 34, 531-549.	1.4	1

#	Article	IF	CITATIONS
541	Determination of Metaâ€Parameters for Support Vector Machine Linear Combinations. Molecular Informatics, 2015, 34, 127-133.	1.4	1
542	Network Variants for Analyzing Target-Ligand Interactions. ACS Symposium Series, 2016, , 35-51.	0.5	1
543	Exploring Molecular Promiscuity from a Ligand and Target Perspective. ACS Symposium Series, 2016, , 19-34.	0.5	1
544	Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors. Methods in Molecular Biology, 2018, 1825, 327-337.	0.4	1
545	Exploration of Target Synergy in Cancer Treatment by Cell-Based Screening Assay and Network Propagation Analysis. Journal of Chemical Information and Modeling, 2019, 59, 3072-3079.	2.5	1
546	Computational Method for Quantitative Comparison of Activity Landscapes on the Basis of Image Data. Molecules, 2020, 25, 3952.	1.7	1
547	Simplified activity cliff network representations with high interpretability and immediate access to SAR information. Journal of Computer-Aided Molecular Design, 2020, 34, 943-952.	1.3	1
548	Minimal screening requirements for identifying highly promiscuous kinase inhibitors. Future Medicinal Chemistry, 2021, 13, 1083-1085.	1.1	1
549	Data Mining Approaches for Compound Selection and Iterative Screening. , 0, , 113-143.		1
550	On data sharing in computational drug discovery and the need for data notes. F1000Research, 2014, 3, 280.	0.8	1
551	Comprehensive knowledge base of two- and three-dimensional activity cliffs for medicinal and computational chemistry. F1000Research, 0, 4, 168.	0.8	1
552	Design of chemical space networks incorporating compound distance relationships. F1000Research, 2016, 5, 2634.	0.8	1
553	Expanding the chemical information science gateway. F1000Research, 2017, 6, 1764.	0.8	1
554	Iterative DeepSARM modeling for compound optimization. Artificial Intelligence in the Life Sciences, 2021, 1, 100015.	1.6	1
555	Deep learning of protein–ligand interactions—Remembering the actors. Artificial Intelligence in the Life Sciences, 2022, 2, 100037.	1.6	1
556	Potency-Scaled Partitioning in Descriptor Spaces with Increasing Dimensionality. Current Topics in Medicinal Chemistry, 2005, 5, 797-803.	1.0	0
557	Inside Cover: From Structure-Activity to Structure-Selectivity Relationships: Quantitative Assessment, Selectivity Cliffs, and Key Compounds (ChemMedChem 11/2009). ChemMedChem, 2009, 4, 1766-1766.	1.6	0
558	Analysis of structure-selectivity relationships through single- or dual step selectivity searching using 2D molecular fingerprints. Chemistry Central Journal, 2009, 3, .	2.6	0

#	Article	IF	CITATIONS
559	Complexity effects in fingerprint similarity searching. Chemistry Central Journal, 2009, 3, .	2.6	Ο
560	Compound Structureâ€Independent Activity Prediction in Highâ€Dimensional Target Space. Molecular Informatics, 2014, 33, 544-558.	1.4	0
561	Complexity and Heterogeneity of Data for Chemical Information Science. ACS Symposium Series, 2016, , 9-17.	0.5	0
562	Virtual Screening for Dual Hsp90/B-Raf Inhibitors. Methods in Pharmacology and Toxicology, 2017, , 355-365.	0.1	0
563	Computationally derived compound profiling matrices. Future Science OA, 2018, 4, FSO327.	0.9	0
564	Data set of activity cliffs with single-atom modification and associated X-ray structure information for medicinal and computational chemistry applications. Data in Brief, 2020, 33, 106364.	0.5	0
565	Evidence for the presence of core structure-dependent activity cliffs. Future Medicinal Chemistry, 2020, 12, 1451-1455.	1.1	0
566	Comprehensive analysis of R-groups in medicinal chemistry. Future Medicinal Chemistry, 2021, , .	1.1	0
567	Searchable database of frequent R-groups in medicinal chemistry and their preferred replacements. Data in Brief, 2021, 39, 107456.	0.5	0
568	[Special Issue for Honor Award dedicating to Prof Kimito Funatsu]Exploring Polypharmacology and Molecular Promiscuity. Journal of Computer Aided Chemistry, 2019, 20, 43-46.	0.3	0
569	Systematic identification of activity cliffs with dualâ€atom replacements and their rationalization on the basis of singleâ€atom replacement analogs and Xâ€ray structures. Chemical Biology and Drug Design, 2022, 99, 308-319.	1.5	0
570	Second-Generation Artificial Intelligence Approaches for Life Science Research. Artificial Intelligence in the Life Sciences, 2021, 1, 100026.	1.6	0
571	Al in Life Science Research – The Road Ahead. Artificial Intelligence in the Life Sciences, 2022, 2, 100030.	1.6	0
572	Understanding uncertainty in deep learning builds confidence. Artificial Intelligence in the Life Sciences, 2022, 2, 100033.	1.6	0
573	Computational analysis, alignmentÂand extension of analogue series from medicinal chemistry. Future Science OA, 0, , .	0.9	0